The global gene editing market is witnessing a surge in growth due to various factors, such as an increase in research and development expenditure in the BRICS, the development of the biotechnological and pharmaceutical sectors, a rise in public and private sector funding for the development of gene editing, the rapid progress of sequencing and genome-editing technologies, the non-labeling of gene-modified products such as GMOs, the utilization of gene-editing in drug discovery processes, and an increased need for synthetic genes. Nevertheless, the North America region held the largest market share in 2021.
Wilmington, Delaware, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report on the global gene editing market size estimated at $3.9 billion in 2021 and is predicted to gain $7.4 billion by 2031, exhibiting a CAGR of 6.7% during the forecast timeframe. This market report provides an in-depth analysis of leading investment pockets, top-performing strategies, market dynamics, market size and forecasts, competitive analysis, and forecast timeframe. It is an essential resource for the emerging market players, and stakeholders to strategically plan and strengthen their competitive edge.
Request Sample of the Report on Gene Editing Market Forecast 2032 - https://www.alliedmarketresearch.com/request-sample/11338
Report Coverage and Details:
Forecast Period | 2022-2031 |
Base Year | 2021 |
Market Size in 2021 | $3.9 Billion |
Market Size in 2031 | $7.4 Billion |
CAGR | 6.7% |
No. of Pages in Report | 297 |
Segments Covered | Technology, End User, Application, and Region |
Drivers | An increase in research and development expenditure in the BRICS |
The development of the biotechnological and pharmaceutical sectors | |
A rise in public and private sector funding for the development of gene editing | |
The rapid progress of sequencing and genome-editing technologies | |
The non-labeling of gene-modified products such as GMOs | |
Restraints | An increase in the cost of genomic equipment |
Opportunities | The growing demand for synthetic genes to make drugs to cure cancer |
The utilization of gene-editing in drug discovery processes |
Recent Developments in the Gene Editing Market
-
In June 2022, Biorad launched SEQuoia express standard library prep kit at AGBT 2022. The SEQuoia Express Stranded RNA Library Prep Kit offers a cost-effective and automation-friendly solution to the current challenges in library generation.
-
In June 2022, Precision BioSciences, Inc. launched ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
-
In April 2022, Takara Bio announced a novel brain-tropic aav vector cereaav for gene therapy.
-
In January 2022, Origene Technologies updated logo for rebranding its expansion from genomics to proteomics OriGene updates its logo, signifying its evolvement from genomic to proteomic market.
-
In December 2021, Thermo Fisher Scientific introduced its new protein, invitrogen truecut hifi cas9 protein, to complement its growing crispr gene editing solutions portfolio.
-
In November 2021, CRISPR therapeutics announced FDA regenerative medicine advanced therapy (rmat) designation granted to CTX110 for the treatment of relapsed or refractory cd19+ b-cell malignancies.
-
In April 2021, Vertex Pharmaceuticals paid CRISPR Therapeutics $900 million in April 2021 to develop, manufacture, and market CRISPR-Cas9 gene-edited treatment for beta-thalassemia and sickle-cell disease.